Caribou Biosciences, INC Form 4 insider transactions

Caribou Biosciences' Chief Technology Officer, Timothy P. Kelly, sold 6,228 shares of common stock for $1.93 per share under a pre-arranged Rule 10b5-1 trading plan.

Caribou Biosciences CTO Timothy P. Kelly reported the acquisition of restricted stock units and stock options, alongside a tax-related sale of common stock.

Caribou Biosciences' Chief Legal Officer, Barbara G. McClung, reported the acquisition of restricted stock units and stock options, alongside a tax-related sale of common stock.

Caribou Biosciences' Chief Business Officer, Ruhi Ahmad Khan, reported the acquisition of restricted stock units and stock options, alongside a sale of common stock to cover tax obligations.

Caribou Biosciences' Chief Medical Officer, Tina M. Albertson, received grants of restricted stock units and stock options, alongside a non-discretionary sale of shares to cover tax obligations.

Caribou Biosciences, Inc. director Ran Zheng was granted options to purchase 45,000 shares of common stock at an exercise price of $1.80 per share.

Caribou Biosciences Director Nancy Whiting was granted options to purchase 45,000 shares of common stock at an exercise price of $1.8 per share.

Caribou Biosciences Director Natalie Sacks was granted options to purchase 45,000 shares of common stock at an exercise price of $1.80 per share.

Caribou Biosciences, Inc. Director Dara Richardson-Heron was granted options to purchase 45,000 shares of common stock at an exercise price of $1.80 per share.

Caribou Biosciences Director David Lee Johnson was granted 45,000 stock options with an exercise price of $1.80, vesting monthly over one year.

Caribou Biosciences Director Andrew Guggenhime was granted options to purchase 45,000 shares of common stock.

Caribou Biosciences director Scott Braunstein acquired 45,000 stock options with a $1.8 exercise price, vesting monthly over one year.

Caribou Biosciences' Chief Financial Officer, Sriram Ryali, acquired 55,000 restricted stock units and options to purchase 247,500 shares of common stock.

Caribou Biosciences' President and CEO, Rachel E. Haurwitz, received significant equity grants including restricted stock units and stock options.

Rachel Haurwitz, President and CEO of Caribou Biosciences, reports the purchase of 20,000 shares of common stock at an average price of $1.02 per share.

Rachel Haurwitz, CEO of Caribou Biosciences, reports the acquisition of restricted stock units and stock options.

Tina M. Albertson, Chief Medical Officer of Caribou Biosciences, Inc., reports the acquisition of stock options and restricted stock units.

Barbara G. McClung, Chief Legal Officer of Caribou Biosciences, reports acquisition of restricted stock units and options, as well as a sale of shares to cover tax obligations.

Ruhi Ahmad Khan, Chief Business Officer of Caribou Biosciences, reports acquisition of restricted stock units and sale of common stock to cover tax obligations.

Timothy P. Kelly, Chief Technology Officer of Caribou Biosciences, acquired 37,500 restricted stock units and options to purchase 170,000 shares of common stock on February 20, 2025.

Steven Kanner, Chief Scientific Officer of Caribou Biosciences, reports acquisition of restricted stock units and options, along with a sale of shares to cover tax obligations.

Director Zheng Ran reports acquisition of options to purchase 40,500 shares of Caribou Biosciences common stock.

Director Nancy Whiting acquired options to purchase 40,500 shares of Caribou Biosciences common stock at an exercise price of $1.41 on February 20, 2025.

Director Natalie Sacks acquired options to purchase 40,500 shares of Caribou Biosciences stock at $1.41 per share.

Dara Richardson-Heron, a director at Caribou Biosciences, acquired options to purchase 40,500 shares of common stock on February 20, 2025.

Director David Lee Johnson acquired options to purchase 40,500 shares of Caribou Biosciences common stock in a transaction dated February 20, 2025.

Director Andrew Guggenhime acquired options to purchase 40,500 shares of Caribou Biosciences common stock on February 20, 2025.

Director Scott Braunstein acquired options to purchase 40,500 shares of Caribou Biosciences common stock at $1.41 per share, vesting monthly until February 20, 2026.

Chief Financial Officer Sriram Ryali reports acquiring 17,360 shares of Caribou Biosciences at $1.42 per share on January 29, 2025.

Caribou Biosciences' Chief Financial Officer, Sriram Ryali, was granted options to purchase 300,000 shares of common stock.